Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 4
2005 1
2006 1
2008 1
2015 1
2020 4
2021 5
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer.
Schatz S, Falk M, Jóri B, Ramdani HO, Schmidt S, Willing EM, Menon R, Groen HJM, Diehl L, Kröger M, Wesseler C, Griesinger F, Hoffknecht P, Tiemann M, Heukamp LC. Schatz S, et al. Among authors: hoffknecht p. Cancers (Basel). 2020 Jun 24;12(6):1685. doi: 10.3390/cancers12061685. Cancers (Basel). 2020. PMID: 32599951 Free PMC article.
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Sebastian M, Eberhardt WEE, Hoffknecht P, Metzenmacher M, Wehler T, Kokowski K, Alt J, Schütte W, Büttner R, Heukamp LC, Stenzinger A, Jänicke M, Fleitz A, Zacharias S, Dille S, Hipper A, Sandberg M, Weichert W, Groschek M, von der Heyde E, Rauh J, Dechow T, Thomas M, Griesinger F; CRISP Registry Group. Sebastian M, et al. Among authors: hoffknecht p. Lung Cancer. 2021 Apr;154:51-61. doi: 10.1016/j.lungcan.2021.02.005. Epub 2021 Feb 13. Lung Cancer. 2021. PMID: 33611226 Free article.
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
Faehling M, Schumann C, Christopoulos P, Hoffknecht P, Alt J, Horn M, Eisenmann S, Schlenska-Lange A, Schütt P, Steger F, Brückl WM, Christoph DC. Faehling M, et al. Among authors: hoffknecht p. Lung Cancer. 2020 Dec;150:114-122. doi: 10.1016/j.lungcan.2020.10.006. Epub 2020 Oct 21. Lung Cancer. 2020. PMID: 33126091
Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.
Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, Christopoulos P, Tufman A, Hoffknecht P, Ulm B, Reich F, Ficker JH, Laack E. Brueckl WM, et al. Among authors: hoffknecht p. Clin Med Insights Oncol. 2020 Aug 19;14:1179554920951358. doi: 10.1177/1179554920951358. eCollection 2020. Clin Med Insights Oncol. 2020. PMID: 32884390 Free PMC article.
Diagnostic, Clinical and Post-SARS-CoV-2 Scenarios in Cancer Patients with SARS-CoV-2: Retrospective Analysis in Three German Cancer Centers.
Shumilov E, Hoffknecht P, Koch R, Peceny R, Voigt S, Schmidt N, Peeck M, Bacher U, Scheithauer S, Trümper L, Lenz G, Kerkhoff A, Bleckmann A. Shumilov E, et al. Among authors: hoffknecht p. Cancers (Basel). 2021 Jun 11;13(12):2917. doi: 10.3390/cancers13122917. Cancers (Basel). 2021. PMID: 34208007 Free PMC article.
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV.
Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, Christopoulos P, Stenzinger A, Tufman A, Hoffknecht P, Ulm B, Reich F, Ficker JH, Laack E. Brueckl WM, et al. Among authors: hoffknecht p. Transl Lung Cancer Res. 2021 Jul;10(7):3093-3105. doi: 10.21037/tlcr-21-197. Transl Lung Cancer Res. 2021. PMID: 34430350 Free PMC article.
16 results